AstraZeneca signs two deals to take companion diagnostics beyond oncology
This article was originally published in Scrip
Executive Summary
The overwhelming majority of currently approved companion diagnostics are for oncology indications, but AstraZeneca wants to change all that and has signed to deals aimed at bringing companion diagnostics to respiratory disorders and heart disease.